OMER News and Press, Omeros Corporation From 10/01/21

Welcome to the "Merck Cures COVID!" edition of Hot Stocks. Of course, the drug maker didn't actually cure the disease. But it did release blockbuster clinical-trial data for an anti-COVID pill that contributed to an overall Wall Street rally. Many segments of the market took the MRK anno...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Today, one of the biggest losers in the market is  Omeros  (NADSAQ: OMER ). Indeed, a decline of 40% in a given day is noteworthy news. And today, OMER stock is unfortunately on the wrong end of deliverin...

The U.S. FDA notified Omeros Corporation ( NASDAQ: OMER ) that it identified deficiencies in the company’s marketing application for Narsoplimab, Omeros disclosed in a press release this morning. Shares of the company tanked more than 40% on Friday. FDA refrained ...

Shares of Omeros (NASDAQ: OMER) , a biopharmaceutical company, are falling today after the company made a disclosure regarding narsoplimab, an experimental treatment to address side effects of stem cell transplants. Shares of the biotech were down 43.7% as of 11:25 a.m. EDT on F...

Gainers: Progenity (NASDAQ:PROG) +29%, Biomerica (NASDAQ:BMRA) +28%, Atea Pharmaceuticals (NASDAQ:AVIR) +19%, Silverback Therapeutics (NASDAQ:SBTX) +13%, Codexis (NASDAQ:CDXS) +12%. Losers: Omeros (NASDAQ:OMER) -41%, Adagio Therapeut...

Omeros Corporation (Nasdaq: OMER) today announced that the U.S. Food and Drug Administration (FDA) notified the company that, as part of FDA’s ongoing review of the company’s Biologics License Application (BLA) for narsoplimab in the treatment of hematopoietic stem ce...

Shares of Omeros Corporation (NASDAQ: OMER) are down 12.2% since Monday. The stock opened at $15.71 on Monday and by Thursday's close, its shares were down to $13.79. The stock is down more than 3% for the year and has been on a slow decline since it reached its 52-week high in Febr...

Omeros' rescheduled PDUFA is upcoming on 10/17/2021. Its chances for gain in case of favorable FDA decision present a compelling risk-reward scenario for shareholders. OMIDRIA is back in growth mode but has yet to prove a sustainable level of revenues. For further details se...

Omeros Corporation (OMER) Q2 2021 Earnings Conference Call August 09, 2021 4:30 PM ET Company Participants Jennifer Williams – Investor Relations Greg Demopulos – Chairman and Chief Executive Officer Nadia Dac – Chief Commercial Officer Mike Jacobsen – Chief Accoun...

Omeros (NASDAQ:OMER): Q2 GAAP EPS of -$0.46 beats by $0.09. Revenue of $28.8M (+112.9% Y/Y) beats by $4.53M. At June 30, 2021, Omeros had cash, cash equivalents and short-term investments available for operations of $73.7 million. Press Release For further details see: Omeros EPS beats ...